Sign In
Buy IRWD
$3.24
-0.0400 (-1.22%)
At Close: Jun 03, 2026
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN 2024 Nutrition Science & Practice Conference
07:30am, Friday, 23'rd Feb 2024
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, announced today that the company will present findings from four studies evaluating apraglutide
Ironwood (IRWD) Q4 Earnings Miss, Revenues Beat Marginally
10:41am, Friday, 16'th Feb 2024
Ironwood's (IRWD) fourth-quarter 2023 earnings lag estimates while revenues beat the same marginally. Linzess collaboration revenues drive the top line.
Ironwood Pharmaceuticals (IRWD) Reports Break-Even Earnings for Q4
09:16am, Thursday, 15'th Feb 2024
Ironwood Pharmaceuticals (IRWD) reported break-even quarterly earnings per share versus the Zacks Consensus Estimate of $0.20. This compares to earnings of $0.27 per share a year ago.
Ironwood (IRWD) is on the Move, Here's Why the Trend Could be Sustainable
09:51am, Monday, 05'th Feb 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Ironwood (IRWD) could be a great choice. It is one of the several stocks that passed through our "Recent Price
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2023 Investor Update Call
04:01pm, Thursday, 01'st Feb 2024
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) today announced it will host its fourth quarter and full year 2023 investor update conference call and webcast at 8:30 a.m. Easte
Wall Street Analysts Think Ironwood (IRWD) Could Surge 37.6%: Read This Before Placing a Bet
10:56am, Tuesday, 23'rd Jan 2024
The consensus price target hints at a 37.6% upside potential for Ironwood (IRWD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate
Ironwood Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference
04:01pm, Wednesday, 03'rd Jan 2024
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today announced that Tom McCourt, CEO, will present at the 42nd Annual J.P. Morgan Healthcare C
Ironwood's (IRWD) Q3 Earnings Miss Mark, Linzess Volume Rises
12:47pm, Friday, 10'th Nov 2023
Ironwood's (IRWD) third-quarter 2023 earnings miss estimates, while revenues beat the same. Linzess collaboration revenues drive the top line.
Ironwood Pharmaceuticals, Inc. (IRWD) Q3 2023 Earnings Call Transcript
10:39am, Thursday, 09'th Nov 2023
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD ) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Matt Roache - Director of Investor Relations Tom McCourt - Chief Executi
Ironwood Pharmaceuticals: The Right Play Now
04:13pm, Friday, 27'th Oct 2023
Ironwood Pharmaceuticals, Inc. is a Boston-based drug company focused on developing treatments for gastrointestinal disorders. The company's revenue-generating product is Linzess, which is approved fo
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a leading global gastrointestinal healthcare company, will present findings during the 2023 North American Society for Pediatric
Ironwood (IRWD) Surges 7.6%: Is This an Indication of Further Gains?
09:01am, Wednesday, 20'th Sep 2023
Ironwood (IRWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the ro
Ironwood: Pipeline Progresses As FDA Approves LINZESS
02:18am, Saturday, 26'th Aug 2023
Ironwood Pharmaceuticals specializes in the development and commercialization of drugs for gastrointestinal diseases, with a focus on conditions like irritable bowel syndrome and chronic constipation.
Ironwood's (IRWD) Reports Q2 Loss, Linzess Volume Rises
10:42am, Wednesday, 09'th Aug 2023
Ironwood (IRWD) reports loss for second-quarter 2023. The top line increases year over year, driven by growth in Linzess collaboration revenues.
3 Lost Formula Stocks to Consider for the 2nd Half of 2023
11:23am, Friday, 07'th Jul 2023
Having ended 2022 on a low note, U.S. market indexes have overall shown stronger performances so far in 2023.
